Cisbio introduces IP-One Terbium. Discover Cisbio's new HTRF Terbium technology and assays

Cisbio Bioassays, member of IBA group, is a global developer of technologies used in assay development and drug screening procedures. Cisbio pioneered the field of homogenous fluorescence methodologies via its proprietary technology, HTRF^®, a highly-sensitive, robust technology platform that improves all research phases for new active molecules from assay development to high throughput screening and lead optimization.

Cisbio is committed to developing new functional tools for enhanced assay implementation in GPCR and kinase screening. Its second generation technology, HTRF Terbium, incorporates Lumi4™-Tb, a terbium cryptate which shows superior stability over other terbium complexes and allows for improved assay performance in terms of sensitivity, assay window, and robustness. Cisbio has already reformatted its IP-One and cAMP assays with Lumi4-Tb to create a terbium platform for assessing all GPCR targets that can be used with any existing HTRF-compatible instrument.

As part of its kinase screening portfolio, Cisbio recently introduced HTRF Transcreener^® ADP, a universal and flexible assay for HTS of all kinases and ATPases, key targets in oncology research. This assay measures the generation of Adenosine 5’-diphosphate and provides enzyme-free detection for less interference and a lower false positive rate than assays which measure ATP depletion.

For more information, visit the company article page.